Floatz logo

Romidepsin

Precancerous Condition

Institut Paoli-CalmettesSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Precancerous Condition cohort.

Asset / SponsorPhaseRating
Darbepoetin Alfa
Mayo Clinic
Phase 3BB
FILGRASTIM
City of Hope Medical Center
Phase 2BB
Epoetin Alfa
Mayo Clinic
Phase 3BB
Cyclophosphamide
Institut Paoli-Calmettes
Phase 2BB
CYCLOSPORIN A
Institut Paoli-Calmettes
Phase 2BB

View all 50 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →